For Research Purposes Only — This article discusses AOD-9604 (a modified fragment of human growth hormone residues 176–191) as a laboratory research compound. The content is intended strictly for researchers, scientists, and educators. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease. All references to human clinical trials are provided as scientific context only and do not constitute medical advice.
Introduction
AOD-9604 is a synthetic peptide derived from the C-terminal region of human growth hormone (hGH). Specifically, it corresponds to residues 176–191 of the 191-residue hGH sequence, with a tyrosine residue added to the N-terminus to aid synthesis and receptor/assay handling. The peptide is therefore often referred to as “HGH fragment 176-191” or as “AOD-9604” (the development code used by Metabolic Pharmaceuticals, the Australian biotechnology company that advanced the molecule through preclinical and early clinical development).
Research interest in the peptide fragment stems from an intriguing hypothesis that emerged in the 1990s. Work by Frank Ng, Michael Wallis, and colleagues at Monash University suggested that the lipolytic (“fat-mobilizing”) and anti-lipogenic activities of full-length hGH could be separated from its classical growth-promoting activities, which are mediated primarily through insulin-like growth factor 1 (IGF-1) via the canonical GH receptor / JAK2 / STAT5 pathway. In rodent models, the C-terminal fragment 176–191 appeared to reproduce hGH’s effects on adipose tissue without producing the same rise in IGF-1 and without the same effects on somatic growth. It was developed as a stabilized analog of this fragment, intended as a potential anti-obesity therapeutic.
That hypothesis drove the compound through Phase I, Phase IIa, and eventually Phase IIb clinical trials for obesity during the early 2000s. The peptide has also been explored in research contexts for its potential effects on cartilage, osteoarthritis models, and general metabolic regulation. This research monograph consolidates what the peer-reviewed literature reports about the fragment’s structure, mechanism, preclinical and clinical metabolic data, and laboratory handling. Every claim is tied to a cited source. Nothing here is medical advice.
Molecular Structure and Biochemistry
Full-length human growth hormone is a 191-amino-acid, single-chain polypeptide with two intramolecular disulfide bonds and a four-helix bundle tertiary structure. The C-terminal region (residues 176–191) forms the penultimate loop of the molecule, lying on the outer surface of the folded protein. This region has historically been of interest because chemically or enzymatically generated C-terminal fragments were reported to retain some of hGH’s metabolic activities.
This lipolytic fragment is a 16-amino-acid sequence (residues 177–191 of hGH, written as LRIVQCRSVEGSCGF) with an additional tyrosine residue at the N-terminus, yielding a 17-amino-acid peptide (Tyr-LRIVQCRSVEGSCGF) with molecular weight of approximately 1,815 Da. The sequence contains two cysteines that form an intramolecular disulfide bond, creating a small constrained loop that is important for bioactivity. The added N-terminal tyrosine facilitates radiolabeling and receptor-binding studies (tyrosines can be iodinated) and improves certain analytical handling properties; it does not appear to be part of the natural hGH sequence.
Because the fragment is derived from a specific surface loop of hGH, it does not engage the full hGH receptor dimerization interface. The classical signaling mechanism of hGH — high-affinity binding to the dimeric hGH receptor, activation of JAK2, and downstream STAT5 phosphorylation leading to IGF-1 gene expression — requires the larger hGH structure. The peptide is too small to reconstitute this interaction, which is consistent with the preclinical observation that it does not meaningfully elevate circulating IGF-1 in animal models at doses producing lipolytic effects.
Physicochemically, the compound is a relatively small, amphipathic peptide. It is moderately water-soluble and is generally supplied as a lyophilized white powder for research use. Its disulfide bond makes it somewhat more stable than purely linear peptides of similar size, though it remains susceptible to oxidative and proteolytic degradation.
Mechanism of Action in Research Models
The lipolytic fragment hypothesis
The foundational idea driving this research program is that the lipolytic activity of hGH can be localized to a specific C-terminal region and separated from its growth-promoting activity. Wilding’s 2004 profile of AOD-9604 in Current Opinion in Investigational Drugs described the program as targeted at obesity and noted that the molecule was developed as a “non-growth-promoting” lipolytic peptide, with Phase IIa trials underway by early 2002 ([DOI unavailable, PMID 15134286]).
The mechanistic picture in rodent preclinical studies is that the fragment stimulates lipolysis in adipose tissue and reduces lipogenesis, producing a net reduction in adiposity in obese animal models without activating the classical hGH receptor / IGF-1 axis. In isolated adipocyte preparations, the peptide has been reported to increase fatty acid release under specific assay conditions, and in obese rodent models, chronic administration has been associated with reductions in body fat mass that are not mirrored by equivalent changes in lean mass or linear growth.
The precise molecular receptor mediating these effects has remained elusive. The peptide does not appear to signal through the classical hGH receptor. Several hypotheses have been proposed — including effects on β-adrenergic signaling pathways or engagement of a distinct receptor that recognizes the C-terminal loop — but no single “AOD-9604 receptor” has been cloned or definitively characterized. This mechanistic ambiguity is one of the reasons the peptide has remained of research interest: it hints at a still-unmapped corner of growth hormone pharmacology.
Adipose tissue and fatty acid metabolism
In preclinical research, the fragment’s effects on adipose tissue can be read out at multiple levels:
- Fatty acid release from isolated adipocytes or adipose tissue explants (a direct lipolytic readout).
- Lipoprotein lipase activity in adipose tissue (lipogenic readout).
- Body composition changes in diet-induced obese rodent models, typically measured by DEXA or by wet-weight dissection of fat pads.
- Gene expression changes in adipose tissue for lipolysis and β-oxidation pathways.
The pattern reported in the literature is that the compound tends to push these readouts in a lipolytic, “fat-catabolizing” direction without producing concurrent changes in circulating IGF-1 or hepatic IGF-1 mRNA — the standard markers of classical hGH receptor activation.
Effects on glucose homeostasis
A recurring interest in this literature is whether the peptide perturbs glucose homeostasis. Full-length hGH, at elevated levels, can induce insulin resistance — a long-recognized complication of classical hGH therapy in adults. One of the reasons separating the lipolytic activity from the growth-promoting activity is attractive is that it might avoid this metabolic side effect. Preclinical data on the fragment’s effects on insulin sensitivity are somewhat mixed, but in the development program it was portrayed as lacking the insulin-resistance signal of full-length hGH.
Broader metabolic context
Jensen’s 2006 review in Obesity placed AOD-9604 within the broader landscape of anti-obesity drug development, identifying it as a growth hormone fragment in clinical trials at the time and framing it as one of several compounds attempting to target adipose tissue function or fatty acid metabolism as a route to weight loss (DOI). Zieba’s 2007 review similarly positioned the peptide alongside other experimental anti-obesity compounds under clinical development, including neurotransmitter modulators, peripheral satiety agents, and thermogenic compounds, noting that it was specifically a human growth hormone fragment in development ([PMID 17971763]).
These contextual reviews are useful because they show how the compound fit into the pharmacological zeitgeist of mid-2000s obesity drug discovery, a period that also saw rimonabant, sibutramine, orlistat, and other agents evaluated with mixed success.
Key Research Areas
Obesity and body composition research
The principal research application of the fragment has been in preclinical obesity models — diet-induced obese (DIO) rodents, genetic obese models (ob/ob, db/db mice), and large-animal studies — where the peptide’s effects on body fat, food intake, and metabolic rate can be characterized. Wilding’s 2004 profile reported that Phase IIa trials in obese human subjects were underway, part of a development program aimed at producing a novel anti-obesity therapeutic based on the lipolytic-fragment hypothesis ([PMID 15134286]).
Publicly available data from the later Phase IIb trials of the compound in obese human subjects did not support advancing the peptide to Phase III for an obesity indication. The compound did not achieve regulatory approval as an anti-obesity drug, and the sponsor’s development program for this indication was ultimately discontinued. For researchers, the Phase IIb data are informative as a cautionary example of how promising preclinical lipolysis signals may not always translate to clinically meaningful body composition changes in humans.
Osteoarthritis and cartilage research
Beyond obesity, the peptide has been explored in preclinical models of osteoarthritis and cartilage regeneration. Although growth hormone’s skeletal effects are primarily mediated through IGF-1, some investigators hypothesized that the fragment might have chondrogenic or cartilage-protective activity independent of the IGF-1 axis. This research area is smaller and less mature than the obesity literature, and the mechanistic basis remains under investigation.
General metabolic and body composition tool compound
In academic research contexts, the fragment is occasionally used as a tool compound for probing the “uncoupling” of lipolytic and growth-promoting activities of growth hormone. For investigators asking questions like “how much of hGH’s metabolic effect is receptor-mediated and how much is attributable to C-terminal fragments?”, this hGH 176-191 analog provides a defined reagent for mechanistic experiments.
Comparison with other GH-related research peptides
AOD-9604 is structurally unrelated to the GHRH analogs (like sermorelin, tesamorelin, and CJC-1295) that act on the pituitary to stimulate endogenous hGH release. It is also distinct from GH secretagogue receptor agonists (like ipamorelin or MK-677) that engage the ghrelin receptor. Its unique niche is as a fragment of hGH itself, rather than as a secretagogue of hGH. Any direct comparison between this peptide and GHRH analogs should account for this fundamental mechanistic difference.
Stability, Storage, and Handling in the Laboratory
The research-grade peptide is typically supplied as a lyophilized white powder. Lyophilized peptide is stable for extended periods at -20 °C, with -80 °C preferred for long-term archival storage. The presence of an intramolecular disulfide bond conveys some additional conformational stability compared to fully linear peptides, but oxidation and disulfide scrambling remain concerns.
Reconstitution is typically performed with sterile water for injection or bacteriostatic water. The peptide generally dissolves readily in aqueous solution without the need for organic cosolvents. Once reconstituted, storage at 2–8 °C for short-term use (days to a few weeks) is standard, and for longer storage the peptide should be aliquoted and frozen at -20 °C. Repeated freeze-thaw cycles should be avoided, particularly for quantitative assays, because each cycle can introduce cumulative degradation and potential disulfide bond rearrangement.
For in vivo rodent research, sterility and endotoxin status must be verified. Sterile filtration through a 0.22 μm low-binding filter is standard prior to administration. Dose preparation for rodent experiments typically starts from a concentrated stock (1–5 mg/mL) and dilutes into the desired working concentration in saline or PBS immediately before use.
Analytical confirmation of peptide identity and purity by HPLC and mass spectrometry is recommended for any lot used in sensitive experiments. For the disulfide-containing fragment, confirming the correct disulfide topology by non-reducing vs reducing mass spectrometry can be important, because misfolded or scrambled material may have different bioactivity than the correctly folded reference.
This handling guidance is for laboratory research use only. The compound is not for human or veterinary administration.
Research Considerations and Limitations
First, the “lipolytic without growth-promoting” hypothesis that drove the development program is elegant but mechanistically underdetermined. The precise receptor or signalling pathway through which the fragment exerts its effects on adipose tissue has not been rigorously mapped, which complicates translation of preclinical findings.
Second, the clinical development program did not produce an approved obesity drug. The Phase IIa signals described in Wilding’s 2004 profile were considered promising, but the subsequent Phase IIb data were ultimately insufficient to advance the compound to Phase III registration trials for obesity ([PMID 15134286]). Researchers should be aware of this clinical trajectory when interpreting preclinical efficacy claims.
Third, literature on the fragment is sparse relative to other peptides in the broader “GH axis” research space. The peptide’s PubMed footprint is much smaller than that of thymosin beta-4 or thymosin alpha-1, and much of the substantive work was done by a single sponsor company and its academic collaborators. External replication of key findings has been limited.
Fourth, in vitro adipocyte lipolysis assays are sensitive to many variables (assay buffer composition, adenosine levels, insulin concentration, adrenergic tone), and reported effect sizes for the peptide can vary considerably between laboratories. Standardized assay protocols and positive controls (e.g., isoproterenol for beta-adrenergic lipolysis) are needed to compare results across studies.
Fifth, the use of this compound outside of a controlled research laboratory context is not supported by any peer-reviewed safety or efficacy data, and no claims about such use are made or implied in this article.
Frequently Asked Research Questions
Q: Is AOD-9604 the same as “HGH fragment 176-191”?
A: The two terms refer to closely related molecules but with a minor distinction. “HGH fragment 176–191” usually refers to the unmodified 16-amino-acid sequence from residues 176–191 of human growth hormone. The compound is the specific development form that corresponds to this region with an added N-terminal tyrosine, yielding a 17-amino-acid peptide with a disulfide bond. In practice, many research suppliers use the two names interchangeably, and researchers should always confirm the exact sequence and modifications from the Certificate of Analysis.
Q: Does AOD-9604 stimulate IGF-1 like full-length growth hormone?
A: Preclinical data indicate that the peptide does not meaningfully elevate circulating IGF-1 at doses producing lipolytic effects in rodent models. This is consistent with its inability to engage the full hGH receptor dimerization interface. The separation of lipolytic and IGF-1-stimulating activities was the central rationale for its development as a candidate anti-obesity peptide ([PMID 15134286]).
Q: Is AOD-9604 an approved weight-loss drug?
A: No. The compound was investigated through Phase IIa and Phase IIb clinical trials for obesity but was not approved by the FDA or other major regulators as an anti-obesity therapeutic. The development program for that indication was ultimately discontinued. Contextual reviews from the period classify it as an experimental compound, not an approved drug (DOI, [PMID 17971763]).
Q: What is the molecular mechanism in adipocytes?
A: The preclinical literature describes the fragment as a lipolytic and anti-lipogenic peptide in adipose tissue, but the precise receptor and intracellular signalling pathway mediating these effects have not been definitively identified. This is a significant gap in the literature and a limitation on mechanistic interpretation.
Q: How should AOD-9604 be stored for research?
A: The lyophilized peptide should be stored at -20 °C or -80 °C, protected from light and moisture. After reconstitution in sterile water or buffer, use within a few weeks at 2–8 °C or aliquot and freeze at -20 °C. Avoid repeated freeze-thaw cycles. Confirm disulfide integrity by mass spectrometry for critical experiments.
References
- Wilding J. AOD-9604 Metabolic. Curr Opin Investig Drugs. 2004;5(4):436-40. PMID: 15134286.
- Zieba R. [Obesity: a review of currently used antiobesity drugs and new compounds in clinical development]. Postepy Hig Med Dosw (Online). 2007;61:612-26. PMID: 17971763.
- Jensen MD. Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors. Obesity (Silver Spring). 2006;14 Suppl 3:143S-149S. PMID: 16931496. DOI
(Citations retrieved from PubMed — https://pubmed.ncbi.nlm.nih.gov)
Disclaimer: All products sold by CertaPeptides are intended for laboratory research use only. Not for human or veterinary use. Not for consumption. Nothing in this article is medical advice, and no statements should be interpreted as claims to diagnose, treat, cure, or prevent any disease. The discontinued clinical development program for this compound in obesity is described here for research-context reference only and does not constitute a recommendation or endorsement of any therapeutic use. Researchers using the peptide in their experiments are responsible for ensuring compliance with all applicable laws, institutional review requirements, and laboratory safety standards.
Researcher Q&A
This question comes from researchers working with AOD-9604 reconstitution in lab settings. The answer reflects the published literature and general peptide solubility chemistry, and is for research-use-only contexts. CertaPeptides compiled this appendix from the technical questions our support team fields most often.
Q: Why does AOD-9604 appear cloudy on reconstitution at 10 mg/mL in bacteriostatic water, and does that indicate a failed batch?
A: Cloudiness at 10 mg/mL AOD-9604 is not unusual and does not automatically indicate a compromised batch. It typically reflects the solubility profile of the fragment at bacteriostatic water pH rather than a quality defect.
AOD-9604 is the C-terminal fragment of hGH (residues 177-191 plus an N-terminal tyrosine, 15 amino acids total). Like the parent hormone, it has limited aqueous solubility near neutral pH. Bacteriostatic water sits around pH 5-6, and for some peptides this region falls close to the isoelectric point — the pH at which net charge is zero and the molecule tends to aggregate. Adding more bacteriostatic water lowers the concentration but does not shift pH in a useful direction.
A commonly cited laboratory practice for borderline-soluble acidic peptides is the addition of a defined, very small quantity of dilute acetic acid, which shifts pH downward and solubilises the peptide. This is a standard SPPS-lab reconstitution approach. It should only be done with a known acid concentration, because undefined additions can drop pH far enough (around pH 3) to accelerate peptide hydrolysis over a period of days.
A practical sequence for a cloudy but otherwise intact AOD-9604 reconstitution is: roll (not shake) at room temperature for approximately ten minutes, then refrigerate for an hour and re-inspect. Slow equilibration frequently clears borderline solutions. Persistent visible particulate or floaters that will not resuspend are distinct from simple cloudiness and typically indicate aggregated peptide, at which point dose linearity is compromised regardless of whether the material is usable.
For lipolytic fragment research in rodent models, the original Monash and Metabolic Pharmaceuticals programme used formulations buffered slightly below neutral pH to maintain the fragment in solution (Wilding 2004, PMID 15134286). This remains the mechanistic baseline for why pH matters with this particular fragment.